Shares of Mineralys Therapeutics, Inc. (MLYS) are soaring 5.22% in Tuesday's trading session, buoyed by a wave of positive analyst actions. Several prominent financial institutions have reiterated their bullish stance on the company while significantly raising their price targets, indicating strong confidence in Mineralys' future prospects.

Leading the charge, Jefferies has increased its target price for MLYS from $26 to $42, representing a substantial 61.5% upside. Wells Fargo followed suit, raising its price target from $50 to $55 while maintaining a Buy rating. Stifel Nicolaus and LifeSci Capital have also reaffirmed their Buy ratings, with price targets set at $45 and $54, respectively. These upgrades suggest that analysts see considerable growth potential in Mineralys Therapeutics' business model and pipeline.

The collective bullish sentiment from multiple analysts is likely driving investor enthusiasm, contributing to the stock's significant intraday gain. As Mineralys Therapeutics continues to attract positive attention from Wall Street, investors will be closely watching for any developments that could further support the company's valuation and growth trajectory.